DOCSLIB.ORG

LIFE-THREATENING CARDIAC ARRYTHMIAS Raluca Tat, Adela Golea

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
LIFE-THREATENING CARDIAC ARRYTHMIAS Raluca Tat, Adela Golea LIFE-THREATENING CARDIAC ARRYTHMIAS Raluca Tat, Adela Golea Educational objectives What you need to know What is a life-threatening arrhythmia How life-threatening arrhythmias are classified What are the signs/symptoms of hemodynamic instability What are the therapeutic options What are the indications of synchronized electrical cardioversion What are the indications of cardiac pacing What are the main indications of antiarrhythmic drugs used in the management patients with arrhythmia What is the antiarrhythmic dosing recommended for the management of patients with arrhythmia What you need to do Identify arrhythmia Identify patients with instability signs/symptoms Choose the appropriate therapeutic option for treating arrhythmia in accordance with the clinical status of the patient and the type of identified arrhythmia Definition Cardiac arrhythmia is a disturbance of the heart rate which may affect the frequency (the alteration of the succession of heartbeats), the regularity of cardiac frequency (the alteration of the ratio between atrial and ventricular rhythms) or both. These changes occur due to a disturbance of myocardial automatism, excitability and contractility, as the heart (body) is subjected to a wide range of pathological (stress) events, such as ischemia, hypoxia, acidosis, electrolyte imbalances, excessive intake of catecholamines, toxic substances etc. Classification: according to origin: sinus, atrial, junctional and ventricular according to heart rate: bradycardia (HR < 60 bpm) and tachycardia (HR > 100 bmp) according to duration: paroxysmal (sudden onset and ending), non-paroxysmal (gradual onset and ending), acute (< 3 weeks) and chronic (> 3 weeks) The correct diagnosis and early treatment of arrhythmias in critical patients may prevent cardiac arrest or the recurrence thereof following a successful resuscitation. Within these circumstances, a series of approach algorithms relating to life- threatening arrhythmias have been issued in order to help out clinicians treat emergency patients as efficiently and as securely as possible. Treatment principles The initial assessment and treatment of patients with arrhythmia must comply with the ABCDE principle and should take into account two aspects: the patient's clinical status (hemodynamically stable or unstable) and the nature of the arrhythmia. The patient's vital signs shall be monitored as soon as possible, at least one peripheral venous access site shall be prepared and specific therappy shall be initiated for all identified abnormalities: o A: open airway o B: breathing rate (BR), SpO2 o C: blood pressure (BP), ventricular rate (VR), hear rate (HR), capillary refill time (CRT) o D: AVPU score1, blood glucose level o E: toxic, environmental factors o Performing 12-lead ECG (specifies rate before treatment or retrospectively – Figure 1 and Figure 2) o The collection of biological samples and the correction of identified abnormalities (e.g. electrolyte imbalances: Mg, Figure 1. ECG waveforms Ca, K) and segments 1 AVPU stands for Alert, Voice, Pain, Unresponsive . The AVPU scale is a simplified Glasgow scale and is used for assessing conscience status. Figure 2. 12-lead ECG. normal RS, PQ, narrow QRS, normal T, normal QT, VR 60/min o Detailed medical history for assessing causes and contexts of arrhythmia onset Antiarrhythmic medication is slower in showing effects and less reliable than electrical cardioversion when the conversion of a life-threatening tachyarrhythmia/ hemodynamic instability clinical phenomena to sinus rhythm is attempted. For these reasons, electrical conversion therapy is usually preferred in patients with signs/symptoms of hemodynamic instability, whereas medication is reserved to patients with no hemodynamic disorder. Signs / Symptoms of hemodynamic instability: The lack or presence of signs/symptoms of hemodynamic instability indicate the most appropriate treatment option for most arrhythmias. o Shock – is characterized by pale and perspired skin, cold and wet limbs (increase of sympathetic activity), alteration of awareness (decrease of brain blood supply) and hypotension (BP < 90 mm Hg). o Syncope – temporary loss of consciousness, following a decrease in the brain's blood supply o Acute heart failure – arrhythmias decrease coronary blood supply and compromise myocardial activity. Signs and symptoms include acute pulmonary edema (left ventricular failure) and/or jugular turgescence and hepatic stasis (right ventricular failure). o Acute myocardial ischemia – occurs when the myocardial oxygen consumption is higher than the supply. It may cause angina (chest pain) or may only lead to isolated changes of the T waveform (sometimes linked to ST segment elevation myocardial infarction), highlighted by 12-lead ECG (silent ischemic lesion or acute coronary syndrome). In case of an underlying coronary or structural heart disease, myocardial ischemia increases the likeliness of severe complications, including heart arrest. Therapeutic options: Once the rhythm has been assessed and the presence/absence of signs/symptoms of hemodynamic instability have been established, the immediate treatment options are: o electrical therapy (cardioversion, pacing) o medication therapy (antiarrhythmics and other drugs) I. Tachyarrhythmias 1. Hemodynamically unstable patient If the patient is hemodynamically unstable (showing any sign/symptom of hemodynamic instability caused by cardiac arrhythmia) and the clinical condition deteriorates, the first treatment choice is synchronized electrical cardioversion. In patients with no cardiovascular conditions in their medical history, instability signs and symptoms are not present at a ventricular rate < 150 beats/minute. Conversely, patients with comorbidities and cardiac dysfunction may be symptomatic and hemodynamically unstable at lower heart rates. If conversion fails to restore normal heart rate and the patient is still unstable, 300 mg IV amiodarone may be given over 10-20 minutes and electrical cardioversion may be repeated if the arrythmia persists. The initial bolus of amiodarone may be followed by a loading dose of 900 mg of amiodarone within the first 24 hours. Repeated electrical cardioversion attempts are not indicated in recurrent atrial fibrillation paroxysmal episodes. These are mostly recommended for critical patients with arrhythmia exacerbation factors, such as sepsis and metabolic dysfunctions. In the mean time, it should be mentioned that electrical cardioversion therapy does not prevent recurrence of arhythmias. If arrhythmia recurrence periods do occur, these are treated with antiarrhythmia medication. Synchronized electrical cardioversion Electrical cardioversion is used for the conversion of atrial or ventricular tachyarrhythmias with pulse. The administered shock is synchronized with the R waveform on the ECG, and not with the T waveform (thus avoiding the relative refractory period and minimizing the risk of inducing ventricular fibrillation). Patients in an aware state require analgesia and sedation prior to the performance of syncrhonized cardioversion. In case of wide complex tachycardia (Figure 3) and atrial fibrillation (AFib, Figure 4), cardioversion is initiated with a 120-150 J biphasic energy. If the initial attempt fails, the energy is increased gradually for the next shocks. Atrial flutter (Figure 5) and paroxysmal supraventricular tachycardia (PSVT, Figure 6) are usually converted at lower energy levels, starting with biphasic 70-120 J. Figure 3. Ventricular tachycardia: wide QRS tachycardia Figure 4. Atrial fibrillation: irregular beat, no P waveform, with F waveform Figure 5. Atrial fibrillation: regular beat, no P waveform, with waveform Figure 6. Supraventricular tachycardia: tachycardia rate, QRS complexes 2. Hemodynamically stable patient Medication can be considered if the patient suffering from tachycardia is hemodynamically stable (no instability signs and symptoms) and is not clinically impaired. Assess the rate (regular/irregular) by 12-lead ECG and establish the duration of the QRS complex. If the duration of the QRS complex is > 0.12 s (3 small squares on the standard ECG paper), the tachycardia is classified as wide complex tachycardia. If the duration of the QRS complex is < 0.12 s, the tachycardia is classified as narrow complex tachycardia. All antiarrhythmic therapeutic options – vagal manoeuvres, medication-based or electrical therapy – may turn out to be pro-arrhythmics. Therefore, the deterioration of the clinical status of the patient may be due to an adverse reaction of the therapy and not necessarily to the lack of effectiveness. The use of multiple doses of various antiarrhythmic substances or of a very high dose of a single antiarrhythmic substance may lead to myocardial depression and hypotension associated with further deterioration of the cardiac rate. A cardiology check-up should be carried out before using repeated doses or combinations of antiarrhythmic drugs. a. Wide QRS tachycardia Wide complex tachycardias usually have a ventricular origin. Although this type of tachycardia may also be caused by supraventricular rhythm with aberrancy, in the case of hemodynamically unstable patients with cardiac arrest risk consider the origin of this type of wide complex tachycardia as ventricular. In hemodynamically stable patients, the next step consists of establishing whether the rhythm is regular or irregular. Wide QRS tachycardia with regular rhythm A wide complex tachycardia with regular rhythm is more likely to be a ventricular
Load more

Recommended publications
  • )&F1y3x PHARMACEUTICAL APPENDIX to THE
    )&f1y3X PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE )&f1y3X PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 3 Table 1. This table enumerates products described by International Non-proprietary Names (INN) which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service (CAS) registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known. Product CAS No. Product CAS No. ABAMECTIN 65195-55-3 ACTODIGIN 36983-69-4 ABANOQUIL 90402-40-7 ADAFENOXATE 82168-26-1 ABCIXIMAB 143653-53-6 ADAMEXINE 54785-02-3 ABECARNIL 111841-85-1 ADAPALENE 106685-40-9 ABITESARTAN 137882-98-5 ADAPROLOL 101479-70-3 ABLUKAST 96566-25-5 ADATANSERIN 127266-56-2 ABUNIDAZOLE 91017-58-2 ADEFOVIR 106941-25-7 ACADESINE 2627-69-2 ADELMIDROL 1675-66-7 ACAMPROSATE 77337-76-9 ADEMETIONINE 17176-17-9 ACAPRAZINE 55485-20-6 ADENOSINE PHOSPHATE 61-19-8 ACARBOSE 56180-94-0 ADIBENDAN 100510-33-6 ACEBROCHOL 514-50-1 ADICILLIN 525-94-0 ACEBURIC ACID 26976-72-7 ADIMOLOL 78459-19-5 ACEBUTOLOL 37517-30-9 ADINAZOLAM 37115-32-5 ACECAINIDE 32795-44-1 ADIPHENINE 64-95-9 ACECARBROMAL 77-66-7 ADIPIODONE 606-17-7 ACECLIDINE 827-61-2 ADITEREN 56066-19-4 ACECLOFENAC 89796-99-6 ADITOPRIM 56066-63-8 ACEDAPSONE 77-46-3 ADOSOPINE 88124-26-9 ACEDIASULFONE SODIUM 127-60-6 ADOZELESIN 110314-48-2 ACEDOBEN 556-08-1 ADRAFINIL 63547-13-7 ACEFLURANOL 80595-73-9 ADRENALONE
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • Medication Appropriateness Index
    Last updated 1/17/2019 Medication Appropriateness Index Patient ID# __________ Evaluator _______________________Date_____________________ Drug Code ____________ Drug___________________________________________________ To assess the appropriateness of the drug, please answer the following questions and circle the applicable rating: 1. Is there an indication for the drug? A________ B_______ C________ Z Indicated Not Indicated DK Comments: 2. Is the medication effective for the A________ B_______ C________ Z condition? Effective Ineffective DK Comments: 3. Is the dosage correct? A________ B_______ C + or C - Z Correct Incorrect DK Comments: 4. Are the directions correct? A_______ B_______ C________ Z Correct Incorrect DK Comments: 5. Are the directions practical? A________ B_______ C________ Z Practical Impractical DK Comments: 6. Are there clinically significant drug- A________ B_______ C________ Z drug interactions? Insignificant Significant DK Comments: 7. Are there clinically significant drug- A________ B_______ C________ Z disease/condition interactions? Insignificant Significant DK Comments: 8. Is there unnecessary duplication with A_______ B_______ C________ Z other drug(s)? Necessary Unnecessary DK Comments: 9. Is the duration of therapy acceptable? A________ B_______ C________ Z Acceptable Not acceptable DK Comments: 10. Is this drug the least expensive A________ B_______ C________ Z alternative compared to others of Least Most DK equal utility? expensive expensive Comments: 1 Last updated 1/17/2019 USE OF THE MEDICATION APPROPRIATENESS INDEX (MAI) For further information/articles using the MAI, address inquiries to Joseph T. Hanlon, PharmD, MS, Department of Medicine (Geriatrics), University of Pittsburgh, Kaufmann Medical Building-Suite 514, 3471 Fifth Ave, Pittsburgh, PA 15213, Email: [email protected] A. General Instructions1 This instrument is intended to assess the appropriateness of medications prescribed by a health care provider and to evaluate patients’ self-medication practices.
    [Show full text]
  • Ventricular Tachycardia Drugs Versus Devices John Camm St
    Cardiology Update 2015 Davos, Switzerland: 8-12th February 2015 Ventricular Arrhythmias Ventricular Tachycardia Drugs versus Devices John Camm St. George’s University of London, UK Imperial College, London, UK Declaration of Interests Chairman: NICE Guidelines on AF, 2006; ESC Guidelines on Atrial Fibrillation, 2010 and Update, 2012; ACC/AHA/ESC Guidelines on VAs and SCD; 2006; NICE Guidelines on ACS and NSTEMI, 2012; NICE Guidelines on heart failure, 2008; NICE Guidelines on Atrial Fibrillation, 2006; ESC VA and SCD Guidelines, 2015 Steering Committees: multiple trials including novel anticoagulants DSMBs: multiple trials including BEAUTIFUL, SHIFT, SIGNIFY, AVERROES, CASTLE- AF, STAR-AF II, INOVATE, and others Events Committees: one trial of novel oral anticoagulants and multiple trials of miscellaneous agents with CV adverse effects Editorial Role: Editor-in-Chief, EP-Europace and Clinical Cardiology; Editor, European Textbook of Cardiology, European Heart Journal, Electrophysiology of the Heart, and Evidence Based Cardiology Consultant/Advisor/Speaker: Astellas, Astra Zeneca, ChanRX, Gilead, Merck, Menarini, Otsuka, Sanofi, Servier, Xention, Bayer, Boehringer Ingelheim, Bristol- Myers Squibb, Daiichi Sankyo, Pfizer, Boston Scientific, Biotronik, Medtronic, St. Jude Medical, Actelion, GlaxoSmithKline, InfoBionic, Incarda, Johnson and Johnson, Mitsubishi, Novartis, Takeda Therapy for Ventricular Tachycardia Medical therapy Antiarrhythmic drugs Autonomic management Ventricular tachycardia Monomorphic Polymorphic Ventricular fibrillation Ventricular storms Ablation therapy Device therapy Surgical Defibrillation Catheter Antitachycardia pacing History of Antiarrhythmic Drugs 1914 - Quinidine 1950 - Lidocaine 1951 - Procainamide 1946 – Digitalis 1956 – Ajmaline 1962 - Verapamil 1962 – Disopyramide 1964 - Propranolol 1967 – Amiodarone 1965 – Bretylium 1972 – Mexiletine 1973 – Aprindine, Tocainide 1969 - Diltiazem 1975- Flecainide 1976 – Propafenone Encainide Ethmozine 2000 - Sotalol D-sotalol 1995 - Ibutilide (US) Recainam 2000 – Dofetilide US) IndecainideX Etc.
    [Show full text]
  • Pharmaceuticals As Environmental Contaminants
    PharmaceuticalsPharmaceuticals asas EnvironmentalEnvironmental Contaminants:Contaminants: anan OverviewOverview ofof thethe ScienceScience Christian G. Daughton, Ph.D. Chief, Environmental Chemistry Branch Environmental Sciences Division National Exposure Research Laboratory Office of Research and Development Environmental Protection Agency Las Vegas, Nevada 89119 [email protected] Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Why and how do drugs contaminate the environment? What might it all mean? How do we prevent it? Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada This talk presents only a cursory overview of some of the many science issues surrounding the topic of pharmaceuticals as environmental contaminants Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada A Clarification We sometimes loosely (but incorrectly) refer to drugs, medicines, medications, or pharmaceuticals as being the substances that contaminant the environment. The actual environmental contaminants, however, are the active pharmaceutical ingredients – APIs. These terms are all often used interchangeably Office of Research and Development National Exposure Research Laboratory, Environmental Sciences Division, Las Vegas, Nevada Office of Research and Development Available: http://www.epa.gov/nerlesd1/chemistry/pharma/image/drawing.pdfNational
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Pharmecovigilance and the Environmental Footprint of Pharmaceuticals Ilene S
    PharmEcovigilance and the Environmental Footprint of Pharmaceuticals Ilene S. Ruhoy, MD, PhD Touro University Nevada Institute for Environmental Medicine Henderson, NV Christian G. Daughton, PhD U.S. Environmental Protection Agency Office of Research and Development Las Vegas, NV US EPA Notice Although this work was reviewed by EPA and approved for publication, it may not necessarily reflect official Agency policy. PPCPs as Environmental Pollutants? PPCPs are a diverse group of chemicals comprising all human and veterinary drugs (available by prescription or over-the-counter, including “biologics”), diagnostic agents (e.g., X-ray contrast media), “nutraceuticals” (bioactive food supplements such as huperzine A), and other consumer chemicals, such as fragrances (e.g., musks) and sun-screen agents (e.g., 4-methylbenzylidene camphor; octocrylene); also included are “excipients” (so-called “inert” ingredients used in PPCP manufacturing and formulation; e.g., parabens). 1st National Survey Revealed Extent of PPCPs in Waterways • USGS “Reconnaissance” study in 1999-2000 was first nationwide investigation of pharmaceuticals, hormones, & other organic contaminants: – 139 streams analyzed in 30 states – 82 contaminants identified (many were pharmaceuticals) – 80% streams had 1 or more contaminant – Average 7 contaminants identified per stream • Since 1998, peer reviewed papers on PPCPs have increased from fewer than 200 per year to greater than 1,000 per year Kolpin DW,et al. "Pharmaceuticals, hormones, and other organic wastewater contaminants
    [Show full text]
  • Medicinal Chemistry
    MEDICINAL CHEMISTRY Cardiovascular Drugs Dr. Bahar Ahmed Reader Dept. of Pharmaceutical Chemistry Faculty of Pharmacy Jamia Hamdard Hamdard Nagar New Delhi-110062 (12.11.2007) CONTENTS Antianginal Drugs Anticoagulants Antihypertensive Agents Cardiac Glycosides Vasodilators Anti-arrhythmic Agents Anti-hyperlipidemic Agents Hypoglycemic Agents Keywords Antianginal Drugs, Anticoagulants, Antihypertensive Agents, Cardiac Glycosides, Vasodilators, Antiarrhythmic Agents, Antihyperlipidemic Agents, Hypoglycemic Agents 1. Antianginal Drugs Introduction The word ‘angina’ derived form the Greek verb meaning to choke and is used to describe the pain or discomfort. Angina occurs when the blood supply to the heart is not able to meet the metabolic demands of the heart for oxygen. Angina pectoris, or ischemic heart diseases, is the name to the symptomatic oppressive pain resulting from myocardial ischemia. An angina may have typical and variant forms, both of which may result in sudden, severe, pressing substantial pain, radiating to the left shoulder and along the flexor surface of the left arm. In typical angina the pain is generally induced by exercise, emotion, or eating. The variant (Prinzmetal’s) angina on the other hand is caused by vasospasm of the coronary vessels and may not be associated with severe atherosclerosis (Fig.1). CHEST PAIN Cardiac Non-cardiac Ischemia Non-ischemic Pulmonary Gastrointestinal - Coronary - Pericarditis (Esophagial spasm) atherosclerosis - Aortic dissection - Coronary spasm - Cardiomyopathies Psychogenic Neuromusculoskeletal - Depression - Anxiety Fig.: Kinds of Pain The antianginal drugs are directed mainly to alleviating and preventing anginal attacks by dilating the coronary artery. Classification of Antianginal drugs 1) Nitrates and nitrites a) Nitrates: e.g. Nitroglycerin (1), Erythritol tetranitrate (2), Trolnitrate phosphate (3), Isosorbide dinitrate (4), Pentaerythritol tetranitrate (5), Mannitol hexanitrate (6).
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, following to be employed in commercial fishing or the commercial UST, MXT, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,456,997 B2 Stauffer Et Al
    USOO9456997B2 (12) United States Patent (10) Patent No.: US 9,456,997 B2 Stauffer et al. (45) Date of Patent: Oct. 4, 2016 (54) SELECTIVE INHIBITION OF (52) U.S. Cl. B1-ADRENERGIC RECEPTORS FOR THE CPC ........... A61K 31/137 (2013.01); A61K 3 1/138 TREATMENT OF PEDIATRC HEART (2013.01); A61K 31/165 (2013.01); A61 K FAILURE 3 1/35 (2013.01); A61K 31/352 (2013.01); (75) Inventors: Brian Stauffer, Aurora, CO (US); A61K 45/06 (2013.01) Carmen Sucharov, Aurora, CO (US); (58) Field of Classification Search Shelley Miyamoto, Aurora, CO (US) CPC ............. A61K 31/137; A61K 31/138: A61 K (73) Assignee: THE REGENTS OF THE 3 1/165; A61K 31/35; A61K 31/352: A61 K UNIVERSITY OF COLORADO, A 45/06 BODY CORPORATE, Denver, CO See application file for complete search history. (US) (56) References Cited (*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S. PATENT DOCUMENTS U.S.C. 154(b) by 215 days. 6,545,040 B1 4/2003 Xhonneux et al. 2007/OO 14733 A1 1/2007 O'Donnell et al. (21) Appl. No.: 13/817,969 (Continued) (22) PCT Filed: Aug. 25, 2011 FOREIGN PATENT DOCUMENTS (86). PCT No.: PCT/US2O11AO49123 WO WO2006130174 * 12/2006 ........... A61K 31,352 S 371 (c)(1), WO WO 2009,1384.51 11/2009 (2), (4) Date: Jun. 6, 2013 OTHER PUBLICATIONS (87) PCT Pub. No.: WO2012/027557 Ahmet et al., “Beneficial effects of chronic pharmacological PCT Pub. Date: Mar. 1, 2012 manipulation of beta-adrenoreceptor Subtype signaling in rodent (65) Prior Publication Data dilated ischemic cardiomyopathy'.
    [Show full text]
  • Profiles of Aprindine, Cibenzoline, Pilsicainide and Pirmenol in The
    REVIEW ARTICLE Jpn Circ J 1999; 63: 1–12 Profiles of Aprindine, Cibenzoline, Pilsicainide and Pirmenol in the Framework of the Sicilian Gambit Itsuo Kodama, MD*; Satoshi Ogawa, MD**; Hiroshi Inoue, MD†; Hiroshi Kasanuki, MD††; Takao Kato, MD‡; Hideo Mitamura, MD**; Masayasu Hiraoka, MD‡‡; Tsuneaki Sugimoto, MD§; The Guideline Committee for Clinical Use of Antiarrhythmic Drugs in Japan (Working Group of Arrhythmias of the Japanese Society of Electrocardiology) The Vaughan Williams classification has been used widely by clinicians, cardiologists and researchers engaged in antiarrhythmic drug development and testing in many countries throughout the world since its initial proposal in the early 1970s. However, a major criticism of the Vaughan Williams system arose from the extent to which the categorization of drugs into classes I–IV led to oversimplified views of both shared and divergent actions. The Sicilian Gambit proposed a two-dimensional tabular framework for display of drug actions to solve these problems. From April to December 1996, members of the Guideline Committee met to discuss pharmacologic profiles of 4 antiarrhythmic drugs (aprindine, cibenzoline, pilsicainide, and pirmenol) that were not included in the original spreadsheet but are used widely in clinical practice in Japan. The discussion aimed to fit the drug profiles into the Gambit framework based on all the important literature published to date regarding the actions of the 4 drugs. This report is a summary of that deliberation. (Jpn Circ J 1999; 63: 1–12) Key Words: Antiarrhythmic drugs; Cardiac electrophysiology; The Sicilian Gambit; The Vaughan Williams classification he Vaughan Williams classification has been used approaches to antiarrhythmic therapy.
    [Show full text]
  • Prediction of Successful Suppression of Sustained Ventricular Tachyarrhythmias by Serial Drug Testing from Data Derived at the Initial Electrophysiologic Study
    CORE Metadata, citation and similar papers at core.ac.uk Provided by Elsevier - Publisher Connector 982 IACC Vol. 12, No . 4 0-be, 1950982-0 Prediction of Successful Suppression of Sustained Ventricular Tachyarrhythmias by Serial Drug Testing From Data Derived at the Initial Electrophysiologic Study DENNIS L . KUCHAR, MD, FRACP, JEFFREY ROTTMAN, MD, ERIC BERGER, MD, CHARLES S . FREEMAN, RN, HASAN GARAN, MD, FACC, JEREMY N . RUSKIN, MD, FACC Boston, Massachusetts This study investigated whether data available after the Subgroup analysis combining each of these variables Iden- initial electrophysldogie study in patients with sustained tified patients with a high, intermediate or low probability ventricular tachyarrhylhmiu could identify those patients of Ending a successful oral drug regimen . Patients whose in whom serial drug testing Is likely to be eficucious, One arrhythmia was suppressed by intravenous procainamlde hundred six patients with Inducible sustained ventricular had a 100% likelihood (If left ventricular ejection fraction tachyarrhythmla, whose initial study included short-term was ?40%) or an 87% likelihood (if ejection traction was drug testing with intravenous procainamWe, were evalu- <40%) of responding to an oral regimen. Patients whose ated, The baseline arrhythmia induced (in the absence of all arrhythmia was still lndaeibie after letravcwuos procaina- antiarrhythmic drugs) was monomorphic tachycardia with mide and had an ejection fraction ?40% had an interme- a cycle length >200 ms in 81 patients and ventricular Purer diate likelihood (46%) of oral drug response. Patients with or fibrillation in the remaining 25 patients. After intrave- persistent ventricular tachycardle after Intravenous pro- nous infusion of procafnamide (1,250 ± 300 mg), a ventric- cainamidc and an ejection fraction <40% had a low ular tachyarrhythada could still be induced in 80 patients probability (19%) of successful response to an oral aatl- during testing with up to three exlrastimuli .
    [Show full text]